KIRKLAND, Wash.--(BUSINESS WIRE)--Prevencio, Inc., The AI-Powered Cardiac Blood Test Company, today announced the Centers for Medicare & Medicaid Services (CMS) has set a National Medicare payment rate of $390.75 for each of the Company’s three lead proprietary HART® cardiac blood tests. The payment rates went into effect January 1, 2023, for Current Procedural Terminology (CPT) billing codes 0308U (for CADhs), 0309U (for HART CVE), and 0310U (for HART KD).
HART CADhs determines whether an adult patient has obstruction of the heart arteries and is at imminent risk of a heart attack, whereas HART CVE improves identification for a patient’s short-to-intermediate risk of heart attack, stroke, or cardiac death. HART KD is the only available test to diagnose whether a child has Kawasaki disease.
“As cardiovascular disease is the leading cause of death in adults in the U.S., there is a tremendous need for both HART CVE and HART CADhs. The Medicare-determined price is additional evidence of the value of HART testing and is an important step in our commercial strategy to establish the HART reimbursement framework,” said Rhonda F. Rhyne, President & Chief Executive Officer of Prevenico. “Building on Medicare’s pricing determination, we will work with commercial, self-insured, and governmental insurance programs, including Medicare and Medicaid, to provide patients with broader access to these important cardiac tests.”
Cardiovascular disease is a global public health epidemic, with 19 million deaths annually. In the U.S., it is the leading cause of death and kills more people than all cancers combined. Cardiovascular disease is also an expensive disease, accounting for more than $378 billion annually in the U.S.
Prevencio is committed to providing clinicians with safer, highly accurate, and more affordable ways to identify the tens of millions of patients at risk for adverse cardiac events. HART tests are valuable for both hospitalized patients and outpatients.
For additional information, visit Prevencio, Inc.
About Prevencio HART Tests:
Powered by AI, Prevencio is revolutionizing blood tests for cardiovascular disease and custom diagnostics. Employing this novel approach, the company has developed seven blood tests that significantly improve diagnoses for a variety of heart and blood vessel-related complications.
Our three lead tests include:
- HART CVE® – 1-year risk of heart attack, stroke, or cardiac death
- HART CADhs® – obstructive coronary artery disease diagnosis
- HART KD® – Kawasaki disease diagnosis
HART test results have been peer-reviewed published 31 times, including at leading cardiovascular meetings—(European Society of Cardiology Congress; American College of Cardiology Scientific Sessions; American Heart Association Scientific Sessions; American Diabetes Association Scientific Sessions; Pediatric Academic Societies International Sessions; International Spinal Cord Society Scientific Sessions; ASTRO Scientific Sessions; and International Kawasaki Disease Symposium) and in top-tier journals—(Journal of American College of Cardiology; American Journal of Cardiology; Clinical Cardiology; Open Heart; Biomarkers in Medicine; Journal of American Heart Association; European Journal of Preventive Cardiology; and International Journal of Cardiology).
About Prevencio, Inc.:
Prevencio's value proposition is "Preventing the Preventable” — That is, preventing unnecessary procedures, related side effects, and expense, as well as improving patient outcomes and clinical trials through more accurate blood tests for cardiovascular disease conditions. Prevencio utilizes Machine Learning (Artificial Intelligence) + Multi-Proteomic Biomarkers + Proprietary Algorithms to deliver cardiovascular diagnostic & prognostic tests that are significantly more accurate than standard-of-care stress tests, clinical and genetic risk scores, and coronary artery calcium scores (CACs). The company is headquartered in Kirkland, Washington. For additional information, visit Prevencio, Inc.
Forward-Looking (Safe Harbor) Statement:
Except for historical and factual information contained herein, this press release contains forward-looking statements, the accuracy of which is necessarily subject to various uncertainties of development-stage companies. The Company does not undertake to update disclosures contained in this press release.